The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM).
A. Keith Stewart
Consultant or Advisory Role - Celgene
Susanna J. Jacobus
No relevant relationships to disclose
Rafael Fonseca
Consultant or Advisory Role - Amgen; Binding Site; Bristol-Myers Squibb; Celgene; Genzyme; Lilly; Medtronic; Millennium; Onyx; Otsuka
Research Funding - Celgene; Onyx
Matthias Weiss
No relevant relationships to disclose
Natalie Scott Callander
No relevant relationships to disclose
Asher Alban Akmal Chanan-Khan
No relevant relationships to disclose
Vincent Rajkumar
No relevant relationships to disclose